Use of plasma biomarkers at exacerbation of chronic obstructive pulmonary disease

被引:326
作者
Hurst, John R.
Donaldson, Gavin C.
Perera, Wayomi R.
Wilkinson, Tom M. A.
Bilello, John A.
Hagan, Gerry W.
Vessey, Rupert S.
Wedzicha, Jadwiga A.
机构
[1] UCL Royal Free & Univ Coll, Sch Med, Acad Unit Resp Med, London NW3 2PF, England
[2] GlaxoSmithKline, Res & Dev, Greenford, Middx, England
[3] GlaxoSmithKline, Res & Dev, Upper Merion, PA USA
[4] GlaxoSmithKline, Res & Dev, Res Triangle Pk, NC USA
关键词
chronic obstructive pulmonary disease; exacerbation; inflammation;
D O I
10.1164/rccm.200604-506OC
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Impact. This study explores the use of measuring plasma biomarkers at exacerbation of chronic obstructive pulmonary disease (COPD), providing insight into the underlying pathogenesis of these important events. Rationale: The use of measuring C-reactive protein (CIRP) to confirm exacerbation, or to assess exacerbation severity, in COPD is unclear. Furthermore, it is not known whether there may be more useful systemic biomarkers. Objective: To assess the use of plasma biomarkers in confirming exacerbation and predicting exacerbation severity. Methods: We assessed 36 biomarkers in 90 paired baseline and exacerbation plasma samples from 90 patients with COPD. The diagnosis of exacerbation fulfilled both health care use and symptom-based criteria. Biomarker concentrations were related to clinical indices of exacerbation severity. Interrelationships between biomarkers were examined to gain information on mechanisms of systemic inflammation at exacerbation of COPD. Measurements and Main Results: To confirm the diagnosis of exacerbation, the most selective biomarker was CRIP. However, this was neither sufficiently sensitive nor specific alone (area under the receiver operating characteristic curve [AUC], 0.73; 95% confidence interval, 0.66-0.80). The combination of CRIP with any one increased major exacerbation symptom recorded by the patient on that day (dyspnea, sputum volume, or sputum purulence) significantly increased the AUC to 0.88 (95% confidence interval, 0.82-0.93; p < 0.0001). There were no significant relationships between biomarker concentrations and clinical indices of exacerbation severity. Interrelationships between biomarkers suggest that the acute-phase response is related, separately, to monocytic and lymphocytic-neutrophilic pathways. Conclusions: Plasma CRP concentration, in the presence of a major exacerbation symptom, is useful in the confirmation of COPD exacerbation. Systemic biomarkers were not helpful in predicting exacerbation severity. The acute-phase response at exacerbation was most strongly related to indices of monocyte function.
引用
收藏
页码:867 / 874
页数:8
相关论文
共 34 条
[1]   ANTIBIOTIC-THERAPY IN EXACERBATIONS OF CHRONIC OBSTRUCTIVE PULMONARY-DISEASE [J].
ANTHONISEN, NR ;
MANFREDA, J ;
WARREN, CPW ;
HERSHFIELD, ES ;
HARDING, GKM ;
NELSON, NA .
ANNALS OF INTERNAL MEDICINE, 1987, 106 (02) :196-204
[2]  
ASHTON CM, 1995, QJM-MON J ASSOC PHYS, V88, P661
[3]   Complement and atherogenesis - Binding of CRP to degraded, nonoxidized LDL enhances complement activation [J].
Bhakdi, S ;
Torzewski, M ;
Klouche, M ;
Hemmes, M .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1999, 19 (10) :2348-2354
[4]   Relation of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbations [J].
Bhowmik, A ;
Seemungal, TAR ;
Sapsford, RJ ;
Wedzicha, JA .
THORAX, 2000, 55 (02) :114-120
[5]   Raised CRP levels mark metabolic and functional impairment in advanced COPD [J].
Broekhuizen, R ;
Wouters, EFM ;
Creutzberg, EC ;
Schols, AMWJ .
THORAX, 2006, 61 (01) :17-22
[6]   Leptin and TNF-alpha levels in patients with chronic obstructive pulmonary disease and their relationship to nutritional parameters [J].
Çalikoglu, M ;
Sahin, G ;
Unlu, A ;
Ozturk, C ;
Tamer, L ;
Ercan, B ;
Kanik, A ;
Atik, U .
RESPIRATION, 2004, 71 (01) :45-50
[7]   Bronchial inflammation in acute bacterial exacerbations of chronic bronchitis:: the role of leukotriene B4 [J].
Crooks, SW ;
Bayley, DL ;
Hill, SL ;
Stockley, RA .
EUROPEAN RESPIRATORY JOURNAL, 2000, 15 (02) :274-280
[8]   C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease [J].
Danesh, J ;
Wheeler, JG ;
Hirschfield, GM ;
Eda, S ;
Eiriksdottir, G ;
Rumley, A ;
Lowe, GDO ;
Pepys, MB ;
Gudnason, V .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (14) :1387-1397
[9]   Value of C-reactive protein measurements in exacerbations of chronic obstructive pulmonary disease [J].
Dev, D ;
Wallace, E ;
Sankaran, R ;
Cunniffe, J ;
Govan, JRW ;
Wathen, CG ;
Emmanuel, FXS .
RESPIRATORY MEDICINE, 1998, 92 (04) :664-667
[10]   Airway and systemic inflammation and decline in lung function in patients with COPD [J].
Donaldson, GC ;
Seemungal, TAR ;
Patel, IS ;
Bhowmik, A ;
Wilkinson, TMA ;
Hurst, JR ;
MacCallum, PK ;
Wedzicha, JA .
CHEST, 2005, 128 (04) :1995-2004